drugset
drugset / Trial / NCT06033742

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

NCT06033742 ↗

Phase 1 Completed 84 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this first-in-human study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of HS-10374 in healthy subjects.

Timeline

Start
2021-11-13
Primary completion
2023-03-24
Completion
2023-03-24

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10374 Unknown — Oral

Indications

psoriasis